Lynx1 Capital Management LP Otonomy, Inc. Transaction History

Lynx1 Capital Management LP

  • $279 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.25 - $2.24 $570,720 - $5.11 Million
2,282,880 Added 7609.6%
2,312,880 $682,000
Q4 2021

Feb 14, 2022
BUY
$1.69 - $2.31 $50,700 - $69,300
30,000 New
30,000 $62,000

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email